NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
Clinical Trials
8 trialsNCT05311579 2022-04-13
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05137171 2021-11-30
AK105 Combined With Anlotinib in Patients With Cervical Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT04731038 2021-09-17
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
Ruijin Hospital
Phase 1 Unknown
NCT04376073 2020-11-25
ANNIE
Sun Yat-sen University
Phase 2 Unknown
NCT04566952 2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04157491 2019-11-08
Anti-PD-1 Antibody Combined With Anlotinib in the Treatment of Endometrial Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT03924882 2019-04-23
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown